Cantor Fitzgerald Comments on Humacyte FY2025 Earnings

Humacyte, Inc. (NASDAQ:HUMA) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Humacyte in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings of ($0.95) per share for the year. The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share.

Several other equities analysts have also recently issued reports on the company. TD Cowen reiterated a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. BTIG Research reiterated a “buy” rating and set a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. D. Boral Capital reissued a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. Finally, Benchmark increased their target price on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $13.71.

Humacyte Price Performance

HUMA opened at $4.59 on Thursday. The business has a fifty day moving average price of $4.52 and a 200 day moving average price of $5.64. Humacyte has a 12 month low of $2.80 and a 12 month high of $9.97. The stock has a market capitalization of $577.70 million, a price-to-earnings ratio of -3.43 and a beta of 1.32.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.08). During the same period last year, the business posted ($0.25) EPS.

Insider Buying and Selling

In other news, CEO Laura E. Niklason sold 261,369 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now directly owns 1,730,884 shares of the company’s stock, valued at approximately $7,615,889.60. This represents a 13.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,500,000 shares of company stock worth $6,606,799 in the last ninety days. 11.20% of the stock is owned by corporate insiders.

Institutional Trading of Humacyte

A number of large investors have recently bought and sold shares of the business. Brookstone Capital Management acquired a new position in Humacyte in the fourth quarter valued at $56,000. ACT Wealth Management LLC acquired a new position in Humacyte in the 4th quarter valued at about $57,000. Concurrent Investment Advisors LLC acquired a new position in Humacyte in the 3rd quarter valued at about $75,000. FORA Capital LLC purchased a new stake in Humacyte during the 3rd quarter valued at approximately $96,000. Finally, Insigneo Advisory Services LLC acquired a new stake in Humacyte during the 3rd quarter worth approximately $109,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.